These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21116089)

  • 1. [Evaluation of neurological symptoms related to hip fracture in a 29-year longitudinal study of subacute myelo-optic-neuropathy (SMON)].
    Konagaya M; Kuru S; Konagaya Y
    Nihon Ronen Igakkai Zasshi; 2010; 47(5):445-51. PubMed ID: 21116089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical Disabilities Related to the Depressive Mental States of Japanese Patients with Subacute Myelo-optico-neuropathy.
    Konishi T
    Intern Med; 2018 Sep; 57(18):2641-2645. PubMed ID: 29780125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of daily living, functional capacity, and life satisfaction of subacute myelo-optico-neuropathy patients in Japan.
    Kamei T; Hashimoto S; Kawado M; Seko R; Ujihira T; Konagaya M; Matsuoka Y
    J Epidemiol; 2009; 19(1):28-33. PubMed ID: 19164868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [SMON--a model of the iatrogenic disease].
    Takasu T
    Rinsho Shinkeigaku; 2003 Nov; 43(11):866-9. PubMed ID: 15152488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis.
    Meade TW
    Br J Prev Soc Med; 1975 Sep; 29(3):157-69. PubMed ID: 127638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression in patients with subacute myelo-optico-neuropathy (SMON).
    Konishi T; Hayashi K; Hayashi M; Ueno S; Yoshida S; Fujimura H; Funakawa I; Kaido M
    Intern Med; 2008; 47(24):2127-31. PubMed ID: 19075537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of disabilities in patients with subacute myelo-optico-neuropathy living at home: satisfaction in daily life and short form-36.
    Takahashi M; Saeki S; Hachisuka K
    Disabil Rehabil; 2009; 31(23):1902-6. PubMed ID: 19479515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fifity years after the identification of the cause of SMON].
    Kuru S
    Rinsho Shinkeigaku; 2021 Feb; 61(2):109-114. PubMed ID: 33504748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anesthetic management of two patients with the history of SMON].
    Sato H; Okawa I; Sasuga M; Mitani S; Matsukawa T; Kumazawa T
    Masui; 2002 Aug; 51(8):907-9. PubMed ID: 12229145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disability and lifestyle of subacute myelo-optico-neuropathy and stroke patients and elderly persons living at home: A comparison of the Barthel Index score and the Frenchay Activities Index score.
    Nagayoshi M; Takahashi M; Saeki S; Hachisuka K
    J UOEH; 2007 Dec; 29(4):407-15. PubMed ID: 18170961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tongue strength in patients with subacute myelo-optico-neuropathy.
    Yamashita S; Nakama T; Ueda M; Honda S; Kimura E; Konagaya M; Ando Y
    J Clin Neurosci; 2018 Jan; 47():84-88. PubMed ID: 29054330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SMON: toxicity of clioquinol and the status quo].
    Konagaya M
    Brain Nerve; 2015 Jan; 67(1):49-62. PubMed ID: 25585435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.
    Konagaya M; Matsumoto A; Takase S; Mizutani T; Sobue G; Konishi T; Hayabara T; Iwashita H; Ujihira T; Miyata K; Matsuoka Y
    J Neurol Sci; 2004 Mar; 218(1-2):85-90. PubMed ID: 14759638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in activities of daily living, functional capacity, and life satisfaction in Japanese patients with subacute myelo-optico-neuropathy.
    Kamei T; Hashimoto S; Kawado M; Seko R; Ujihira T; Konagaya M
    J Epidemiol; 2010; 20(6):433-8. PubMed ID: 20827034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clioquinol intoxication occurring in the treatment of acrodermatitis enteropathica with reference to SMON outside of Japan.
    Hanakago R; Uono M
    Clin Toxicol; 1981 Dec; 18(12):1427-34. PubMed ID: 6460590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Aggravation of Depression with Aging in Japanese Patients with Subacute Myelo-optico-neuropathy (SMON).
    Konishi T; Hayashi K; Sugiyama H
    Intern Med; 2017 Aug; 56(16):2119-2123. PubMed ID: 28781313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prevalence of dementia in subacute myelo-optico-neuropathy (SMON) patients who underwent medical checkups].
    Saito Y; Sakai K; Konagaya M
    Nihon Ronen Igakkai Zasshi; 2016; 53(2):152-7. PubMed ID: 27250222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micturitional disturbance in subacute myelo-optico-neuropathy (SMON).
    Sakakibara R; Hattori T; Uchiyama T; Yamanishi T
    Auton Neurosci; 2001 Mar; 87(2-3):282-5. PubMed ID: 11476290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals.
    Tateishi J
    Neuropathology; 2000 Sep; 20 Suppl():S20-4. PubMed ID: 11037182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of SMON at 30 years after its outbreak ending: special reference to those patients with blindness].
    Konagaya M; Matsuoka Y; Nakae K; Iwashita H
    No To Shinkei; 2002 Jun; 54(6):473-80. PubMed ID: 12166096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.